Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
7
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Damora Therapeutics Inc. market cap is $1.34B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Damora Therapeutics Inc. 52 week high is $38.33 as of November 15, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Damora Therapeutics Inc. 52 week low is $15.76 as of November 15, 2026.
Damora Therapeutics Inc. stock price today is $21.60.
Damora Therapeutics Inc. stock price yesterday was $22.05.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Damora Therapeutics Inc.'s P/E ratio is -0.18.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Damora Therapeutics Inc. P/B ratio is 3.6568.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Damora Therapeutics Inc. 50-day moving average is $22.19.
